Damora Therapeutics (DMRA) Gains from Investment Securities (2020 - 2026)
Damora Therapeutics (DMRA) reported Gains from Investment Securities of $4.0 million for Q1 2026, up 2579.35% on a YoY basis from $151000.0 in Q1 2025, and up 707.48% quarter-over-quarter from -$666000.0 in Q4 2025.
Damora Therapeutics (DMRA) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Damora Therapeutics has reported Gains from Investment Securities for 7 years, with the latest figure at $4.0 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 2579.35% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (up 243.88% YoY), and the FY2025 full-year result was $983375.0, up 342.8% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $4.0 million, up from -$666000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $7.7 million in Q2 2023, with the low at -$1.9 million in Q4 2024.
- Historically, Gains from Investment Securities has averaged $1.5 million across 5 years, with a median of $401979.0 in 2023.
- Annual changes were most pronounced in 2024 — Gains from Investment Securities tumbled 2424.68% — and 2026, when it jumped 2579.35%.
- Damora Therapeutics' Gains from Investment Securities stood at -$942000.0 in 2022, then surged by 91.83% to -$77000.0 in 2023, then plunged by 2424.68% to -$1.9 million in 2024, then surged by 65.74% to -$666000.0 in 2025, then surged by 707.48% to $4.0 million in 2026.
- The last three Gains from Investment Securities figures came in at $4.0 million (Q1 2026), -$666000.0 (Q4 2025), and $241132.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Damora Therapeutics | 731.26 Mn | 528.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.05 Mn |
| Mar 31, 2026 | 4.05 Mn |
| Dec 31, 2025 | -666,000.00 |
| Dec 31, 2025 | -666,000.00 |
| Jun 30, 2025 | 241,132.00 |
| Jun 30, 2025 | 241,132.00 |
| Mar 31, 2025 | 151,000.00 |
| Mar 31, 2025 | 151,000.00 |
| Dec 31, 2024 | -1.94 Mn |
| Dec 31, 2024 | -1.94 Mn |
| Sep 30, 2024 | 182,205.00 |
| Sep 30, 2024 | 182,205.00 |
| Jun 30, 2024 | 1.44 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Dec 31, 2023 | -77,000.00 |
| Dec 31, 2023 | -77,000.00 |
| Sep 30, 2023 | 401,979.00 |
| Sep 30, 2023 | 401,979.00 |
| Jun 30, 2023 | 7.67 Mn |
| Jun 30, 2023 | 7.67 Mn |